莱斯康制药与诺和诺德启动口服肥胖症候选药物Lx9851的一期临床研究

美股速递
Yesterday

莱斯康制药与诺和诺德公司联合宣布,双方已正式启动口服肥胖症治疗候选药物Lx9851的一期临床试验。该研究旨在评估Lx9851在人体中的安全性、耐受性及药代动力学特征,标志着这一新型口服疗法研发进程的重要里程碑。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10